Drug intelligence / Profile preview

BR1733

Development stage: Phase 2
Lead developer: Shanghai Blueray Biopharma
Modality: Small Molecules
Administration: Oral

Overview

BR1733 is an orally bioavailable small molecule inhibitor targeting the embryonic ectoderm development (EED) protein, a core component of the polycomb repressive complex 2 (PRC2). By binding to EED, BR1733 disrupts PRC2 function and inhibits its histone methyltransferase activity, leading to reduced trimethylation of histone H3 at lysine 27 (H3K27me3), chromatin de-repression, and potential antitumor effects. The drug is being developed primarily for advanced cancers including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), refractory follicular lymphoma, and other solid tumors. It is currently in Phase 1/2 clinical trials. BR1733 was initially developed by Shanghai Blueray Biopharma.

Other names: eed inhibitor br1733

Targets

EED (Embryonic ectoderm development protein)

Beyond the preview

Go deeper on BR1733.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1733.

Explore the full profile